SOFT TISSUE & BONE SARCOMA GROUP

Visit Tumour page

EORTC 1809 – STRASS II – A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (RPS)

Retroperitoneal sarcoma is a very rare tumour, occurring in 0.5 to 1.0 per 100,000 of the population. Diagnosis and treatment are challenging. The standard of care consists currently of surgery. Overall patient survival at 5 years following surgery is between
60 and 70%.

The EORTC 1809 STRASS II study is the first official trial looking into potential benefits of chemotherapy before surgery to improve disease control and survival in patients burdened by this rare cancer.

Contact us

SOFT TISSUE & BONE SARCOMA GROUP

EORTC Cancer Research Fund
Visit Tumour page

EORTC 1809 – STRASS II – A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (RPS)

Retroperitoneal sarcoma is a very rare tumour, occurring in 0.5 to 1.0 per 100,000 of the population. Diagnosis and treatment are challenging. The standard of care consists currently of surgery. Overall patient survival at 5 years following surgery is between
60 and 70%.

The EORTC 1809 STRASS II study is the first official trial looking into potential benefits of chemotherapy before surgery to improve disease control and survival in patients burdened by this rare cancer.

Contact us

Clinical Trial

Clinical Trial Phase

Phase III

Arrow

Cancer type

EORTC Cancer Research Fund Cancer Type

Sarcoma

Arrow

Set up

Set-Up

EORTC & Intergroups

Arrow

Status

Status

Recruiting

Clinical trial:

Clinical Trial Phase

Phase III

Down Arrow

Cancer type:

EORTC Cancer Research Fund Cancer Type

Sarcoma

Down Arrow

Set up:

Set-Up

EORTC & Intergroups

Down Arrow

Status:

Status

Recruiting

KEY STUDY MILESTONES

KEY STUDY MILESTONES

Dr Winan van Houdt

“STRASS II is a breakthrough for a rare but devastating disease. It also emphasizes the importance of multinational collaborations in fighting rare cancers.”

Dr Winan van Houdt, Netherlands Kanker Instituut,
EORTC STRASS II Study Co-Ordinator
Dr Alessandro Gronchi

“STRASS II is the result of the big commitment of EORTC in academic research and in rare cancers. The challenge of building a global study, open in Europe, North America, Australia and Japan is won. A global study to improve the outcome of RPS patients worldwide.”

Dr Alessandro Gronchi, IRCCS - Fondazione Istituto Nazionale dei Tumori, Milano, STRASS II Study Coordinator
Lydie Meheus

“We very much appreciate that the EORTC involves its network and expertise in clinical trials to solve patient-centred needs in a non-profit way. Because innovative valuable treatments for patients do not always yield commercial value. Successful treatment of cancer is not only about new drugs but also about quality surgery, radiotherapy and combinatorial interventions even including generic drugs. Especially these initiatives, outside the scope of commercial developers need encouragement.”

Lydie Meheus, Anticancer Fund managing director

STUDY STATUS

Country activation

Soft Tissue Bone Sarcoma - Study status

Patient recruitment

*Last update July 2022

STUDY STATUS

Country activation

Soft Tissue Bone Sarcoma - Study status

Patient recruitment

*Last update July 2022

STUDY STATUS

To view the Study Status map, please flip your phone horizontally:

Do you have any question on the EORTC STRASS II clinical trial?

Contact us

Do you have any question on the EORTC STRASS II clinical trial?

Contact us

FUNDING PARTNERS

International grants

National grants

EORTC Cancer Research Fund anticancerfund logo 500x190 2022 e1657713223361
Climbers Against Cancer
Sarcoma UK - Logo
Cancer Research UK
Novo Nordisk DK - Logo

FUNDING PARTNERS

International grants

EORTC Cancer Research Fund anticancerfund logo 500x190 2022 e1657713223361
Climbers Against Cancer

National grants

Sarcoma UK - Logo
Cancer Research UK
Novo Nordisk DK - Logo